vs
CNA FINANCIAL CORP（CNA）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是CNA FINANCIAL CORP的2.0倍（$772.1M vs $389.0M），CNA FINANCIAL CORP净利率更高（77.6% vs 12.7%，领先64.9%），Revvity同比增速更快（5.9% vs -2.0%），CNA FINANCIAL CORP自由现金流更多（$542.0M vs $161.8M），过去两年Revvity的营收复合增速更高（9.0% vs -2.2%）
CNA金融公司是总部位于美国伊利诺伊州芝加哥的金融企业，旗下核心子公司大陆意外伤害保险公司成立于1897年，大陆保险公司的历史则可追溯至1853年，当前母公司CNA于1967年正式注册成立，在保险及金融服务领域拥有深厚的行业积淀。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
CNA vs RVTY — 直观对比
营收规模更大
RVTY
是对方的2.0倍
$389.0M
营收增速更快
RVTY
高出7.9%
-2.0%
净利率更高
CNA
高出64.9%
12.7%
自由现金流更多
CNA
多$380.2M
$161.8M
两年增速更快
RVTY
近两年复合增速
-2.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $389.0M | $772.1M |
| 净利润 | $302.0M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 97.2% | 14.5% |
| 净利率 | 77.6% | 12.7% |
| 营收同比 | -2.0% | 5.9% |
| 净利润同比 | 1338.1% | 3.9% |
| 每股收益（稀释后） | $1.11 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CNARVTY
| Q4 25 | $389.0M | $772.1M | ||
| Q3 25 | $393.0M | $698.9M | ||
| Q2 25 | $398.0M | $720.3M | ||
| Q1 25 | $397.0M | $664.8M | ||
| Q4 24 | $397.0M | $729.4M | ||
| Q3 24 | $401.0M | $684.0M | ||
| Q2 24 | $404.0M | $691.7M | ||
| Q1 24 | $407.0M | $649.9M |
净利润CNARVTY
| Q4 25 | $302.0M | $98.4M | ||
| Q3 25 | $403.0M | $46.7M | ||
| Q2 25 | $299.0M | $53.9M | ||
| Q1 25 | $274.0M | $42.2M | ||
| Q4 24 | $21.0M | $94.6M | ||
| Q3 24 | $283.0M | $94.4M | ||
| Q2 24 | $317.0M | $55.4M | ||
| Q1 24 | $338.0M | $26.0M |
毛利率CNARVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率CNARVTY
| Q4 25 | 97.2% | 14.5% | ||
| Q3 25 | — | 11.7% | ||
| Q2 25 | 95.5% | 12.6% | ||
| Q1 25 | 87.9% | 10.9% | ||
| Q4 24 | 5.3% | 16.3% | ||
| Q3 24 | 90.0% | 14.3% | ||
| Q2 24 | 99.5% | 12.4% | ||
| Q1 24 | — | 6.8% |
净利率CNARVTY
| Q4 25 | 77.6% | 12.7% | ||
| Q3 25 | 102.5% | 6.7% | ||
| Q2 25 | 75.1% | 7.5% | ||
| Q1 25 | 69.0% | 6.4% | ||
| Q4 24 | 5.3% | 13.0% | ||
| Q3 24 | 70.6% | 13.8% | ||
| Q2 24 | 78.5% | 8.0% | ||
| Q1 24 | 83.0% | 4.0% |
每股收益（稀释后）CNARVTY
| Q4 25 | $1.11 | $0.86 | ||
| Q3 25 | $1.48 | $0.40 | ||
| Q2 25 | $1.10 | $0.46 | ||
| Q1 25 | $1.00 | $0.35 | ||
| Q4 24 | $0.07 | $0.77 | ||
| Q3 24 | $1.04 | $0.77 | ||
| Q2 24 | $1.17 | $0.45 | ||
| Q1 24 | $1.24 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | $3.0B | — |
| 股东权益账面价值 | $11.6B | $7.3B |
| 总资产 | $69.4B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.26× | — |
8季度趋势，按日历期对齐
现金及短期投资CNARVTY
| Q4 25 | — | $919.9M | ||
| Q3 25 | — | $931.4M | ||
| Q2 25 | — | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $1.7B |
总债务CNARVTY
| Q4 25 | $3.0B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $3.0B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益CNARVTY
| Q4 25 | $11.6B | $7.3B | ||
| Q3 25 | $11.3B | $7.4B | ||
| Q2 25 | $10.7B | $7.6B | ||
| Q1 25 | $10.3B | $7.6B | ||
| Q4 24 | $10.5B | $7.7B | ||
| Q3 24 | $10.8B | $7.9B | ||
| Q2 24 | $9.9B | $7.9B | ||
| Q1 24 | $9.7B | $7.8B |
总资产CNARVTY
| Q4 25 | $69.4B | $12.2B | ||
| Q3 25 | $69.8B | $12.1B | ||
| Q2 25 | $68.9B | $12.4B | ||
| Q1 25 | $67.3B | $12.4B | ||
| Q4 24 | $66.5B | $12.4B | ||
| Q3 24 | $67.4B | $12.8B | ||
| Q2 24 | $65.2B | $13.4B | ||
| Q1 24 | $65.1B | $13.4B |
负债/权益比CNARVTY
| Q4 25 | 0.26× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $570.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $542.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 139.3% | 21.0% |
| 资本支出强度资本支出/营收 | 7.2% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.89× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $2.4B | $509.4M |
8季度趋势，按日历期对齐
经营现金流CNARVTY
| Q4 25 | $570.0M | $182.0M | ||
| Q3 25 | $720.0M | $138.5M | ||
| Q2 25 | $562.0M | $134.3M | ||
| Q1 25 | $638.0M | $128.2M | ||
| Q4 24 | $703.0M | $174.2M | ||
| Q3 24 | $748.0M | $147.9M | ||
| Q2 24 | $616.0M | $158.6M | ||
| Q1 24 | $504.0M | $147.6M |
自由现金流CNARVTY
| Q4 25 | $542.0M | $161.8M | ||
| Q3 25 | $704.0M | $120.0M | ||
| Q2 25 | $538.0M | $115.5M | ||
| Q1 25 | $620.0M | $112.2M | ||
| Q4 24 | $665.0M | $149.8M | ||
| Q3 24 | $730.0M | $125.6M | ||
| Q2 24 | $597.0M | $136.6M | ||
| Q1 24 | $484.0M | $129.7M |
自由现金流率CNARVTY
| Q4 25 | 139.3% | 21.0% | ||
| Q3 25 | 179.1% | 17.2% | ||
| Q2 25 | 135.2% | 16.0% | ||
| Q1 25 | 156.2% | 16.9% | ||
| Q4 24 | 167.5% | 20.5% | ||
| Q3 24 | 182.0% | 18.4% | ||
| Q2 24 | 147.8% | 19.7% | ||
| Q1 24 | 118.9% | 20.0% |
资本支出强度CNARVTY
| Q4 25 | 7.2% | 2.6% | ||
| Q3 25 | 4.1% | 2.6% | ||
| Q2 25 | 6.0% | 2.6% | ||
| Q1 25 | 4.5% | 2.4% | ||
| Q4 24 | 9.6% | 3.4% | ||
| Q3 24 | 4.5% | 3.3% | ||
| Q2 24 | 4.7% | 3.2% | ||
| Q1 24 | 4.9% | 2.7% |
现金转化率CNARVTY
| Q4 25 | 1.89× | 1.85× | ||
| Q3 25 | 1.79× | 2.97× | ||
| Q2 25 | 1.88× | 2.49× | ||
| Q1 25 | 2.33× | 3.03× | ||
| Q4 24 | 33.48× | 1.84× | ||
| Q3 24 | 2.64× | 1.57× | ||
| Q2 24 | 1.94× | 2.87× | ||
| Q1 24 | 1.49× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CNA
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
